The development of the new RNAi vector system that is effective in analysis and therapy of leukemia and cranial nerve disease.
Project/Area Number |
22590043
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Physical pharmacy
|
Research Institution | Yokohama College of Pharmacy |
Principal Investigator |
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | ドラックデリバリー / 遺伝子 / 発現抑制 / 薬学 / 発現制御 |
Research Abstract |
In this study, we developed the RNAi vector system which expressed siRNA in cytoplasm using T7 RNA polymerase. The co-transfection of pCMV-T7RNAP and pT7-RNAi-Lu significantly suppressed luciferase expression by pGL3-control plasmid in HeLa cells and A549 cells. Moreover, the co-transfection of pCMV-T7RNAP and pT7-RNAi-p53 significantly suppressed p53 protein expression in HeLa cells. Thus, we were able to confirm that the new vector system using T7 RNA polymerase has function to suppress the expression of target gene.
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] a novel regulator of cardiomyogenesis in pluripotent embryonic cells2011
Author(s)
Yasuda S, Hasegawa T, Hosono T, Satoh M, Watanabe K, Ono K, Shimizu S, Hayakawa T, Yamaguchi T, Suzuki K, Sato Y.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-